Glucose Variability in Type 1 Diabetes (T1D) and Glycaemic Responses to Food Composition.
NCT ID: NCT06546657
Last Updated: 2025-03-19
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
96 participants
Study Classification
OBSERVATIONAL
Study Start Date
2021-02-06
Study Completion Date
2021-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study proposed to recruit approximately 435 children and young people who have T1D and who regularly use Dexcom continuous glucose monitoring (CGM). Recruitment was be via their local dietitian. The dietitian was asked to provide baseline information about the participants which will include demographic data and information on clinical data, treatment and anthropometrics. Participants will be asked to provide access to Dexcom CGM data throughout the period of recording. Participants were issued with, for seven consecutive days, two survey questionnaires, one in the morning at breakfast time and the other in the evening. The morning survey will include questions on the breakfast meal (including a photograph of the meal) and insulin dosage, similarly the evening survey will also include questions on diabetes management and food and fluid intake in addition to questions on activities all of which took place during the four-hour postprandial period. These data will be statistically described using univariate, bivariate and multivariate analysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes
NCT01586065
Type 1 Diabetes
COMPLETED
NA
Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D
NCT04614623
Type1diabetes
UNKNOWN
NA
Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
NCT01439672
Type 1 Diabetes Mellitus
COMPLETED
NA
CGM Use in Poorly Controlled Youth With Type 1 Diabetes
NCT04721145
Type 1 Diabetes
Hypoglycemia
High Blood Sugar
COMPLETED
NA
Determinants of Glycaemic Control in Children With Type 1 Diabetes
NCT06325111
Diabetes Mellitus, Type 1
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a quantitative observational study. Dexcom CGM data was collected for the period recording. Retrospective CGM data was collected to assess glucose variability during the day and night time periods. The Participants were then asked to provide information for seven days about their breakfast meal and the four hour post meal period. This included information on the type of meal consumed, a photograph of the meal and their diabetes management for the meal for example the insulin dose amount and timing. For the four hour post meal period the participants were asked about any adjustments they had to make to their diabetes management for example the treatment of high or low glucose readings, any snacks they ate and any activities they took part in. They were also asked to describe their mood during the post meal period.
Recruitment - Paediatric diabetes dietitians, working across the United Kingdom (UK), were enrolled to help recruit participants and become principal investigators (PI) for their site.
As this was an observational study there was no power calculation. The sample size was calculated from the number of dietitians that were likely to be available to help with recruitment; this was estimated to be around 32 and was based on the number that had already been approached. It was felt that they would have capacity to recruit 13-14 participants and this would result in 435 participants.
Methodology Baseline data
In order to make comparisons between relevant variables and glucose levels, the following baseline data will be collected from the dietitians and sent to the chief investigator, along with the artificial identifier on the Excel spreadsheet as discussed earlier at the stage of recruitment of participants:
Parent's email address Sex, date of birth and recent weight and height (for calculation of BMI and BMI centile) and date of when this was taken Date of diagnosis of T1D Last four HbA1c Total daily insulin dose (TDD) Insulin: carbohydrate ratios (ICR) and Insulin Sensitivity Factor (ISF) Current insulin regimen - including the type of insulin prescribed and if applicable type of insulin pump i.e. open or closed loop system.
Glucose measurement data on interstitial glucose was be collected via Dexcom CGM. The Dexcom CGM data will be accessed by a research 'Clarity Clinic' with Dexcom CLARITY® Clinic Portal (Dexcom In, San Diego, California (CA), USA). The researcher was the administrator of this clinic. Once the local dietitian had recruited, the participant's parent's email address will be sent to the researcher along with the baseline information/data as described above. The researcher, as administrator of the Clarity Clinic account, then invited the participant, via email, to be added to the clinic. Once the invite has been accepted, it stood for the period of the recording i.e. until all the seven day breakfast recording period was completed. Once the participant had submitted their last questionnaire, they were removed from the Dexcom CLARITY® Clinic Portal.
The participants were not asked to make changes to their diabetes management and their breakfast meal. The participants were asked to submit two daily questionnaires (a morning and post-meal questionnaire) for seven days about their breakfast meal and the postprandial period and email a photograph of the breakfast meal.
The morning questionnaire was about the breakfast meal and included the following questions:
Participant's artificial identifier Date (of when meal was taken) The total average daily insulin dose (both bolus and basal insulin) if known (participant will only be asked to provide this once) Food eaten at breakfast including portion size, type and brand Drinks taken at breakfast including volume, type and brand The total carbohydrate count of breakfast in grams The number of units of insulin taken with breakfast How many units were given for a correction dose The type of bolus (for those on an insulin pump) The time of when the insulin dose was administered The time that breakfast started and ended How the bolus was calculated The amount of breakfast that was consumed (all, ¾, ½, ¼, none)
The post meal questionnaire included the following questions:
Participant's artificial identifier Date (of when meal was taken) Details of any hypo's in the four-hour postprandial period (time, treatment) Details of correction doses given in the four-hour postprandial period (whether in response to Dexcom CGM, times and number of units if insulin) Details of snacks taken in the four-hour postprandial period (type and amount of carbohydrate, responses to Dexcom CGM, number of units of insulin) Details of drinks taken in the four-hour postprandial period (volume, type/brand, carbohydrate amount if applicable) Details of any other adjustments made to insulin and or carbohydrate Type and duration of all physical activities undertaken during the 4-hour post prandial period Details of insulin adjustments made for physical activities Details of any addition information e.g. mood, menstruating, illness, stressors
Data analysis This will be a mix of univariate, bivariate and multivariate analysis as this is best suited to describing, summarising and visualising these data. Outputs will include the distribution of glucose levels post-breakfast to determine the spread and dispersion of the data.
Recruitment - Paediatric diabetes dietitians, working across the United Kingdom (UK), were enrolled to help recruit participants and become principal investigators (PI) for their site.
As this was an observational study there was no power calculation. The sample size was calculated from the number of dietitians that were likely to be available to help with recruitment; this was estimated to be around 32 and was based on the number that had already been approached. It was felt that they would have capacity to recruit 13-14 participants and this would result in 435 participants.
Methodology Baseline data
In order to make comparisons between relevant variables and glucose levels, the following baseline data will be collected from the dietitians and sent to the chief investigator, along with the artificial identifier on the Excel spreadsheet as discussed earlier at the stage of recruitment of participants:
Parent's email address Sex, date of birth and recent weight and height (for calculation of BMI and BMI centile) and date of when this was taken Date of diagnosis of T1D Last four HbA1c Total daily insulin dose (TDD) Insulin: carbohydrate ratios (ICR) and Insulin Sensitivity Factor (ISF) Current insulin regimen - including the type of insulin prescribed and if applicable type of insulin pump i.e. open or closed loop system.
Glucose measurement data on interstitial glucose was be collected via Dexcom CGM. The Dexcom CGM data will be accessed by a research 'Clarity Clinic' with Dexcom CLARITY® Clinic Portal (Dexcom In, San Diego, California (CA), USA). The researcher was the administrator of this clinic. Once the local dietitian had recruited, the participant's parent's email address will be sent to the researcher along with the baseline information/data as described above. The researcher, as administrator of the Clarity Clinic account, then invited the participant, via email, to be added to the clinic. Once the invite has been accepted, it stood for the period of the recording i.e. until all the seven day breakfast recording period was completed. Once the participant had submitted their last questionnaire, they were removed from the Dexcom CLARITY® Clinic Portal.
The participants were not asked to make changes to their diabetes management and their breakfast meal. The participants were asked to submit two daily questionnaires (a morning and post-meal questionnaire) for seven days about their breakfast meal and the postprandial period and email a photograph of the breakfast meal.
The morning questionnaire was about the breakfast meal and included the following questions:
Participant's artificial identifier Date (of when meal was taken) The total average daily insulin dose (both bolus and basal insulin) if known (participant will only be asked to provide this once) Food eaten at breakfast including portion size, type and brand Drinks taken at breakfast including volume, type and brand The total carbohydrate count of breakfast in grams The number of units of insulin taken with breakfast How many units were given for a correction dose The type of bolus (for those on an insulin pump) The time of when the insulin dose was administered The time that breakfast started and ended How the bolus was calculated The amount of breakfast that was consumed (all, ¾, ½, ¼, none)
The post meal questionnaire included the following questions:
Participant's artificial identifier Date (of when meal was taken) Details of any hypo's in the four-hour postprandial period (time, treatment) Details of correction doses given in the four-hour postprandial period (whether in response to Dexcom CGM, times and number of units if insulin) Details of snacks taken in the four-hour postprandial period (type and amount of carbohydrate, responses to Dexcom CGM, number of units of insulin) Details of drinks taken in the four-hour postprandial period (volume, type/brand, carbohydrate amount if applicable) Details of any other adjustments made to insulin and or carbohydrate Type and duration of all physical activities undertaken during the 4-hour post prandial period Details of insulin adjustments made for physical activities Details of any addition information e.g. mood, menstruating, illness, stressors
Data analysis This will be a mix of univariate, bivariate and multivariate analysis as this is best suited to describing, summarising and visualising these data. Outputs will include the distribution of glucose levels post-breakfast to determine the spread and dispersion of the data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 1 Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Breakfast
Breakfast meal
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children and young people aged between 1-17 years
* Diagnosis of type 1 diabetes for a minimum of one year
* Using multiple daily injections (MDI) together with carbohydrate counting or Continuous Subcutaneous Insulin Infusion (CSII)
* Using Dexcom continuous glucose monitoring (CGM) on a regular basis.
* Access to internet and email
* Diagnosis of type 1 diabetes for a minimum of one year
* Using multiple daily injections (MDI) together with carbohydrate counting or Continuous Subcutaneous Insulin Infusion (CSII)
* Using Dexcom continuous glucose monitoring (CGM) on a regular basis.
* Access to internet and email
Exclusion Criteria
* Prescribed anti-hyperglycaemia agents i.e. Glucophage (Metformin) and or antidepressants.
* Have other medical conditions, including complications of diabetes and coeliac disease will be excluded.
* Currently enrolled in another research study
* Have other medical conditions, including complications of diabetes and coeliac disease will be excluded.
* Currently enrolled in another research study
Minimum Eligible Age
1 Year
Maximum Eligible Age
17 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Stirling
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julie Johnson, MNutr
Role: PRINCIPAL_INVESTIGATOR
University of Stirling
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Health Sciences and Sport
Stirling, Stirlingshire, United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Barnea-Goraly N, Raman M, Mazaika P, Marzelli M, Hershey T, Weinzimer SA, Aye T, Buckingham B, Mauras N, White NH, Fox LA, Tansey M, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL; Diabetes Research in Children Network (DirecNet). Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care. 2014 Feb;37(2):332-40. doi: 10.2337/dc13-1388. Epub 2013 Dec 6.
Reference Type
RESULT
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Norgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub 2019 Jun 8.
Reference Type
RESULT
Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care. 2015 Jun;38(6):1008-15. doi: 10.2337/dc15-0100.
Reference Type
RESULT
Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010 Apr 29;464(7293):1293-300. doi: 10.1038/nature08933.
Reference Type
RESULT
Bode BW, Johnson JA, Hyveled L, Tamer SC, Demissie M. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. Diabetes Technol Ther. 2017 Jan;19(1):25-33. doi: 10.1089/dia.2016.0350. Epub 2017 Jan 5.
Reference Type
RESULT
Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001 Nov;24(11):1858-62. doi: 10.2337/diacare.24.11.1858.
Reference Type
RESULT
Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 2017 Jul;40(7):951-957. doi: 10.2337/dc16-1770. Epub 2017 May 8.
Reference Type
RESULT
Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science. 1978 Apr 7;200(4337):21-7. doi: 10.1126/science.635569.
Reference Type
RESULT
Buse JB, Carlson AL, Komatsu M, Mosenzon O, Rose L, Liang B, Buchholtz K, Horio H, Kadowaki T. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab. 2018 Dec;20(12):2885-2893. doi: 10.1111/dom.13545. Epub 2018 Oct 10.
Reference Type
RESULT
Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987 Oct;22(4):487-97. doi: 10.1002/ana.410220408.
Reference Type
RESULT
Danne T, Phillip M, Buckingham BA, Jarosz-Chobot P, Saboo B, Urakami T, Battelino T, Hanas R, Codner E. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018 Oct;19 Suppl 27:115-135. doi: 10.1111/pedi.12718. No abstract available.
Reference Type
RESULT
Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care. 2003 Oct;26(10):2728-33. doi: 10.2337/diacare.26.10.2728.
Reference Type
RESULT
DiMeglio LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pillay K, Maahs DM. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018 Oct;19 Suppl 27:105-114. doi: 10.1111/pedi.12737. No abstract available.
Reference Type
RESULT
Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986 May 22;314(21):1360-8. doi: 10.1056/NEJM198605223142106. No abstract available.
Reference Type
RESULT
Faber EM, van Kampen PM, Clement-de Boers A, Houdijk ECAM, van der Kaay DCM. The influence of food order on postprandial glucose levels in children with type 1 diabetes. Pediatr Diabetes. 2018 Jun;19(4):809-815. doi: 10.1111/pedi.12640. Epub 2018 Mar 12.
Reference Type
RESULT
Gandrud LM, Xing D, Kollman C, Block JM, Kunselman B, Wilson DM, Buckingham BA. The Medtronic Minimed Gold continuous glucose monitoring system: an effective means to discover hypo- and hyperglycemia in children under 7 years of age. Diabetes Technol Ther. 2007 Aug;9(4):307-16. doi: 10.1089/dia.2007.0026.
Reference Type
RESULT
Gingras V, Taleb N, Roy-Fleming A, Legault L, Rabasa-Lhoret R. The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes. Diabetes Obes Metab. 2018 Feb;20(2):245-256. doi: 10.1111/dom.13052. Epub 2017 Aug 10.
Reference Type
RESULT
Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, Ritterband LM, Magee JC, Cox DJ, Clarke WL. Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care. 2009 Jun;32(6):1001-6. doi: 10.2337/dc08-1722. Epub 2009 Mar 26.
Reference Type
RESULT
Heptulla RA, Allen HF, Gross TM, Reiter EO. Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy. Pediatr Diabetes. 2004 Mar;5(1):10-5. doi: 10.1111/j.1399-543X.2004.00035.x.
Reference Type
RESULT
Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, King GL. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 1993 Jan;42(1):80-9. doi: 10.2337/diab.42.1.80.
Reference Type
RESULT
Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care. 1996 Jul;19(7):689-97. doi: 10.2337/diacare.19.7.689.
Reference Type
RESULT
Lopez PE, Evans M, King BR, Jones TW, Bell K, McElduff P, Davis EA, Smart CE. A randomized comparison of three prandial insulin dosing algorithms for children and adolescents with Type 1 diabetes. Diabet Med. 2018 Oct;35(10):1440-1447. doi: 10.1111/dme.13703. Epub 2018 Jun 19.
Reference Type
RESULT
Mangrola D, Cox C, Furman AS, Krishnan S, Karakas SE. SELF BLOOD GLUCOSE MONITORING UNDERESTIMATES HYPERGLYCEMIA AND HYPOGLYCEMIA AS COMPARED TO CONTINUOUS GLUCOSE MONITORING IN TYPE 1 AND TYPE 2 DIABETES. Endocr Pract. 2018 Jan;24(1):47-52. doi: 10.4158/EP-2017-0032. Epub 2017 Nov 16.
Reference Type
RESULT
Marzelli MJ, Mazaika PK, Barnea-Goraly N, Hershey T, Tsalikian E, Tamborlane W, Mauras N, White NH, Buckingham B, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL; Diabetes Research in Children Network (DirecNet). Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes. 2014 Jan;63(1):343-53. doi: 10.2337/db13-0179. Epub 2013 Oct 29.
Reference Type
RESULT
Mauras N, Mazaika P, Buckingham B, Weinzimer S, White NH, Tsalikian E, Hershey T, Cato A, Cheng P, Kollman C, Beck RW, Ruedy K, Aye T, Fox L, Arbelaez AM, Wilson D, Tansey M, Tamborlane W, Peng D, Marzelli M, Winer KK, Reiss AL; Diabetes Research in Children Network (DirecNet). Longitudinal assessment of neuroanatomical and cognitive differences in young children with type 1 diabetes: association with hyperglycemia. Diabetes. 2015 May;64(5):1770-9. doi: 10.2337/db14-1445. Epub 2014 Dec 8.
Reference Type
RESULT
Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, Wilson DM, Tansey MJ, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL; Diabetes Research in Children Network (DirecNet). Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes. 2016 Feb;65(2):476-85. doi: 10.2337/db15-1242. Epub 2015 Oct 28.
Reference Type
RESULT
McDonnell CM, Northam EA, Donath SM, Werther GA, Cameron FJ. Hyperglycemia and externalizing behavior in children with type 1 diabetes. Diabetes Care. 2007 Sep;30(9):2211-5. doi: 10.2337/dc07-0328. Epub 2007 Jun 11.
Reference Type
RESULT
Perantie DC, Wu J, Koller JM, Lim A, Warren SL, Black KJ, Sadler M, White NH, Hershey T. Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care. 2007 Sep;30(9):2331-7. doi: 10.2337/dc07-0351. Epub 2007 Jun 15.
Reference Type
RESULT
Perantie DC, Lim A, Wu J, Weaver P, Warren SL, Sadler M, White NH, Hershey T. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes. 2008 Apr;9(2):87-95. doi: 10.1111/j.1399-5448.2007.00274.x. Epub 2008 Jan 12.
Reference Type
RESULT
Perantie DC, Koller JM, Weaver PM, Lugar HM, Black KJ, White NH, Hershey T. Prospectively determined impact of type 1 diabetes on brain volume during development. Diabetes. 2011 Nov;60(11):3006-14. doi: 10.2337/db11-0589. Epub 2011 Sep 27.
Reference Type
RESULT
Piechowiak K, Dzygalo K, Szypowska A. The additional dose of insulin for high-protein mixed meal provides better glycemic control in children with type 1 diabetes on insulin pumps: randomized cross-over study. Pediatr Diabetes. 2017 Dec;18(8):861-868. doi: 10.1111/pedi.12500. Epub 2017 Jan 24.
Reference Type
RESULT
Ryan RL, King BR, Anderson DG, Attia JR, Collins CE, Smart CE. Influence of and optimal insulin therapy for a low-glycemic index meal in children with type 1 diabetes receiving intensive insulin therapy. Diabetes Care. 2008 Aug;31(8):1485-90. doi: 10.2337/dc08-0331. Epub 2008 May 5.
Reference Type
RESULT
Smart CE, King BR, McElduff P, Collins CE. In children using intensive insulin therapy, a 20-g variation in carbohydrate amount significantly impacts on postprandial glycaemia. Diabet Med. 2012 Jul;29(7):e21-4. doi: 10.1111/j.1464-5491.2012.03595.x.
Reference Type
RESULT
Smart CE, Evans M, O'Connell SM, McElduff P, Lopez PE, Jones TW, Davis EA, King BR. Both dietary protein and fat increase postprandial glucose excursions in children with type 1 diabetes, and the effect is additive. Diabetes Care. 2013 Dec;36(12):3897-902. doi: 10.2337/dc13-1195. Epub 2013 Oct 29.
Reference Type
RESULT
Smart CE, Annan F, Higgins LA, Jelleryd E, Lopez M, Acerini CL. ISPAD Clinical Practice Consensus Guidelines 2018: Nutritional management in children and adolescents with diabetes. Pediatr Diabetes. 2018 Oct;19 Suppl 27:136-154. doi: 10.1111/pedi.12738. No abstract available.
Reference Type
RESULT
Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S120-7. doi: 10.2337/dc11-s206.
Reference Type
RESULT
Tansey M, Beck R, Ruedy K, Tamborlane W, Cheng P, Kollman C, Fox L, Weinzimer S, Mauras N, White NH, Tsalikian E; Diabetes Research in Children Network (DirecNet). Persistently high glucose levels in young children with type 1 diabetes. Pediatr Diabetes. 2016 Mar;17(2):93-100. doi: 10.1111/pedi.12248. Epub 2014 Dec 11.
Reference Type
RESULT
Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401.
Reference Type
RESULT
The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996 Oct;45(10):1289-98.
Reference Type
RESULT
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
273640
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With T1DM?
NCT02371694
COMPLETED
NA
Glycemic Control and the Brain in Children With Type 1 Diabetes
NCT03428932
COMPLETED
NA
Pilot Study of Remote Glucose Monitoring Among Pediatric Patients With Type 1 Diabetes
NCT04696640
COMPLETED
NA
Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes
NCT04614168
COMPLETED
NA
Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy
NCT01104142
COMPLETED
Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections
NCT02465411
COMPLETED
NA
Glycemic Profiles And Insulin Delivery Across The Menstrual Cycle In Women With Type 1 Diabetes
NCT04665999
COMPLETED
Comparison Between Hypoglycemic Counter Regulatory Responses in Type 1 Diabetics vs Control Subjects
NCT03034226
COMPLETED
NA
Effect of CSII and CGM on Progression of Late Diabetic Complications
NCT01454700
COMPLETED
PHASE4
Prevalence of Nocturnal Hypoglycemia in Children on a Type 1 Diabetes (TID) Insulin Regimen Using a Continuous Glucose Monitoring System (CGMS)
NCT00542334
COMPLETED
The Effect of Insulin During Exercise on the Development of Low Blood Sugar in Individuals With Type I Diabetes
NCT00147342
COMPLETED
Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus
NCT01418703
COMPLETED
NA
Continue Glucose Monitoring Before Insulin Pump
NCT02813421
COMPLETED
NA
Information, Follow-up and Early Diagnosis of Children at Risk for Type 1 Diabetes
NCT06676566
ENROLLING_BY_INVITATION
Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D
NCT04335513
UNKNOWN
NA
CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)
NCT03263494
COMPLETED
PHASE3
Effects of a Remote Patient Monitoring Protocol on Glycemic Control in Adolescents With Type 1 Diabetes
NCT03466398
WITHDRAWN
NA
Glycaemic Load and Pre-meal Insulin Doses in Type 1 Diabetes Patients
NCT01978704
COMPLETED
NA
Risk Factors of Metabolic Control in Children and Adolescents With Type 1 Diabetes
NCT03642470
COMPLETED
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
NCT04668612
UNKNOWN
NA
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
NCT01401751
COMPLETED
NA
Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes
NCT04053712
COMPLETED
PHASE4
Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes
NCT00727220
COMPLETED
Flexible, Intensive Insulin Therapy in Patients With Type 1 Diabetes
NCT00595569
COMPLETED